Cargando…
Disease Risk and GVHD Biomarkers Can Stratify Patients For Risk of Relapse and Non-Relapse Mortality Post Hematopoietic Cell Transplant
The graft-versus-leukemia (GVL) effect after allogeneic hematopoietic cell transplant (HCT) can prevent relapse but the risk of severe graft-vs-host disease (GVHD) leads to prolonged intensive immunosuppression and possible blunting of the GVL effect. Strategies to reduce immunosuppression in order...
Autores principales: | Aziz, Mina D., Shah, Jay, Kapoor, Urvi, Dimopoulos, Christina, Anand, Sarah, Augustine, Allan, Ayuk, Francis, Chaudhry, Mohammed, Chen, Yi-Bin, Choe, Hannah K., Etra, Aaron, Gergoudis, Stephanie, Hartwell, Matthew J., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kowalyk, Steven, Kröger, Nicolaus, Merli, Pietro, Morales, George, Nakamura, Ryotaro, Ordemann, Rainer, Pulsipher, Michael A., Qayed, Muna, Reshef, Ran, Rösler, Wolf, Schechter, Tal, Schreiner, Elisabeth, Srinagesh, Hrishikesh, Wölfl, Matthias, Wudhikarn, Kitsada, Yanik, Gregory, Young, Rachel, Özbek, Umut, Ferrara, James L.M., Levine, John E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332389/ https://www.ncbi.nlm.nih.gov/pubmed/32020045 http://dx.doi.org/10.1038/s41375-020-0726-z |
Ejemplares similares
-
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
por: Etra, Aaron, et al.
Publicado: (2022) -
The utility of biomarkers in acute GVHD prognostication
por: Spyrou, Nikolaos, et al.
Publicado: (2023) -
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
por: Akahoshi, Yu, et al.
Publicado: (2023) -
Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023) -
Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)